MDT-AP-0706
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 6
- os_event
- false
- age_years
- 40
- new_clusters
- S1
- umap1_2d
- -1.741653939
- umap2_2d
- -10.99360268
- umap1_3d
- -1.463108477
- umap2_3d
- -1.134467103
- umap3_3d
- 3.88587519
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.440
- KRAS_SIGNALING_DN+0.370
- SPERMATOGENESIS+0.140
- MYOGENESIS+0.040
- BILE_ACID_METABOLISM+0.030
- APICAL_SURFACE-0.010
- ALLOGRAFT_REJECTION-0.030
- COAGULATION-0.030
- INFLAMMATORY_RESPONSE-0.050
- KRAS_SIGNALING_UP-0.060
Top 10 suppressed
- PROTEIN_SECRETION-0.540
- UNFOLDED_PROTEIN_RESPONSE-0.530
- TGF_BETA_SIGNALING-0.520
- MTORC1_SIGNALING-0.490
- MYC_TARGETS_V2-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- MITOTIC_SPINDLE-0.420
- DNA_REPAIR-0.410
- G2M_CHECKPOINT-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CF-A3MF-01A-12R-A21D-07 | — | — | 0.983 |
| 2 | MNG597 | — | — | 0.981 |
| 3 | TCGA-DK-A1A7-01A-11R-A13Y-07 | — | — | 0.979 |
| 4 | msclc569389_S35.txt | — | cohortMD1 | 0.978 |
| 5 | MNG599 | — | — | 0.976 |
| 6 | 08e3d239-3d8a-4eee-9e08-ac2bcb3f2619 | — | — | 0.973 |
| 7 | MNG1259 | — | — | 0.969 |
| 8 | SRR1366141 | GTEX | — | 0.967 |
| 9 | MNG598 | — | — | 0.966 |
| 10 | SRR12696785 | — | — | 0.965 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.440 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.370 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| MYOGENESIS | 0.040 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |